{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:01:53Z","timestamp":1784851313067,"version":"3.55.0"},"reference-count":5,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tierarztl Prax Ausg K Kleintiere Heimtiere"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Im Jahr 2025 kamen f\u00fcr Kleintiere 3 neue Wirkstoffe auf den deutschen\n                    Arzneimittelmarkt: die beiden Janus-Kinase-Hemmer Atinvicitinib und Ilunocitinib\n                    zur Behandlung von Juckreiz bei allergischer oder atopischer Dermatitis und der\n                    Serotonin-Wiederaufnahme-Hemmer Fluoxetin zur unterst\u00fctzenden Behandlung bei\n                    trennungsbedingten Verhaltensauff\u00e4lligkeiten. Kein Wirkstoff erhielt eine\n                    Erweiterung auf weitere Tierarten. Neu f\u00fcr Kleintiere auf dem Markt sind: 2\n                    Wirkstoffe (Benazepril, Pimobendan) mit je einer neuen Darreichungsform, ein\n                    Wirkstoff (Meloxicam) mit neuer Darreichungsform und Wirkstoffgehalt, 3\n                    Wirkstoffe bzw. Kombinationen (Enflicoxib, Milbemycinoxim+Praziquantel,\n                    Tramadol) mit neuem Wirkstoffgehalt, eine neue Wirkstoffkombination\n                    (Terbinafin+Betamethasonacetat) sowie 2 Wirkstoffe (Metoclopramid, Mirtazapin)\n                    mit neuen Packungsgr\u00f6\u00dfen. Es gab keine neuen Impfstoffe f\u00fcr Kleintiere im Jahr\n                    2025.<\/jats:p>","DOI":"10.1055\/a-2875-2161","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:30:31Z","timestamp":1782945031000},"page":"193-199","source":"Crossref","is-referenced-by-count":0,"title":["Neue Arzneimittel f\u00fcr Kleintiere 2025"],"prefix":"10.1055","volume":"54","author":[{"given":"Anika","family":"L\u00fcttig","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmakologie, Pharmazie und Toxikologie,\n                    Veterin\u00e4rmedizinische Fakult\u00e4t der Universit\u00e4t Leipzig"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin Jana","family":"Kamutzki","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmakologie, Pharmazie und Toxikologie,\n                    Veterin\u00e4rmedizinische Fakult\u00e4t der Universit\u00e4t Leipzig"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka Ute","family":"Emmerich","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmakologie, Pharmazie und Toxikologie,\n                    Veterin\u00e4rmedizinische Fakult\u00e4t der Universit\u00e4t Leipzig"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL(\u00ae)) is a novel Janus kinase inhibitor with activity against\n                    cytokines involved in allergy","volume":"37","author":"A J Gonzales","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jvp.70022","article-title":"Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs","volume":"49","author":"K Boerngen","year":"2026","journal-title":"J Vet Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12917-025-04579-1","article-title":"Safety of ilunocitinib tablets (Zenrelia\u2122) after once daily oral administration\n                    in dogs","volume":"21","author":"E A Kuntz","year":"2025","journal-title":"BMC Vet Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases\n                    with Janus kinase inhibitors: a consensus statement","volume":"80","author":"P Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2376\/1439-0299-2021-23","article-title":"Antibiotikaeinsatz und Resistenzentwicklung bei Hund und Katze unter dem\n                    Einfluss der T\u00c4HAV-Novelle 2018 \u2013 ein Stimmungsbild Berliner Tier\u00e4rzte","volume":"135","author":"M Moerer","year":"2022","journal-title":"Berl M\u00fcnch Tier\u00e4rztl Wochenschr"}],"container-title":["Tier\u00e4rztliche Praxis Ausgabe K: Kleintiere \/ Heimtiere"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2875-2161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:31:02Z","timestamp":1784849462000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2875-2161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":5,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2875-2161","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1434-1239","2567-5842"],"issn-type":[{"value":"1434-1239","type":"print"},{"value":"2567-5842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}